|
Title
|
In Vivo Effects of Antiglaucomatous Prostglandin Therapy on Immune Cells, Epithelium, and Nerves of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study
|
|
MEEI Protocol ID
|
11-007H
|
|
National Clinical Trial (NCT) Number
|
NCT01315574 |
|
Condition
|
Glaucoma
|
|
Sponsor
|
Alcon Research Ltd.
|
|
Principal Investigator
|
Pedram Hamrah, M.D.
|
|
Study Design
|
Treatment, parallel assignment, Double blind (Subject, Care giver, Investigator), Randomized
|
|
Study Objective
|
|
|
Who is Eligible
|
Healthy adults, 18 and over, with Glaucoma disease, who have never used anti-glaucoma drops.
|
|
Subject Enrollment
|
We are currently enrolling individuals who have glaucoma who meet the study eligibility criteria.
|
|
Study Procedures
|
Participation in this study involves 4 visits to our Ocular Surface Imaging Center for an eye exam and corneal imaging over a period of 6 months in conjunction to your regularly scheduled glaucoma service consultation, each of which could last up to 45 additional minutes. The findings will allow us to compare the effects of each of the drops on the ocular surface of the eye. Each participant will be given a 6-month supply of glaucoma drops once they have passed the screening and will be asked to follow the prescribed regimen of treatment.
Study participants will be equally randomized to receive one of two anti-glaucoma drops: Travatan Z (SofZia-containing) or Xalatan (BAK-containing). Both anti-glaucoma drops are considered equally effective at controlling glaucoma disease and are FDA-approved standard anti-glaucoma regimen. We would like to use the information gathered from this research study to examine if there are any differences at the cellular level between the corneas of patients using these different glaucoma drops.
|
|
For More Information
|
Cornea Research 617-573-3313
|
Please click here to return to the Ophthalmology Clinical Research page.
Page updated 8/6/2012.
